Nationwide Incidence, Treatment Pattern, and Prognosis of Primary CNS Lymphoma in Taiwan, 2012-2020: A Retrospective Cohort Study - PubMed
8 hours ago
- #Primary CNS Lymphoma
- #Epidemiology
- #Survival Analysis
- The study analyzed 820 PCNSL patients in Taiwan (2012-2020), with a median age of 65 years; 94.4% were DLBCL subtype.
- Age-standardized incidence was 0.39 per 100,000 person-years, higher in males (0.44) and the elderly (1.62 for ages ≥75 years).
- Median survival was 1.85 years, with survival rates decreasing sharply with age—ranging from 5.71 years for under 50 to 0.69 years for ages ≥80.
- MTX-based chemotherapy with rituximab use increased from 22.2% to 55.3%, leading to better survival (3.44 years) compared to WBRT alone (1.24 years).
- Relapsed/refractory disease occurred in 46.2% of patients at a median of 156 days, and common adverse events included infection (87.9%) and nausea/vomiting (81.1%).
- First-year healthcare costs averaged $35,472 USD, highlighting a significant burden despite high induction therapy rates (89.5% received treatment within 24 days).